{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:18:53Z","timestamp":1787239133586,"version":"build-2736575974"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Zenas BioPharma, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40744-026-00835-4","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T17:01:03Z","timestamp":1773680463000},"page":"867-880","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and Safety of Obexelimab to Treat IgG4-Related Disease: Protocol for a Global, Randomized, Placebo-Controlled Trial"],"prefix":"10.1007","volume":"13","author":[{"given":"Emma L.","family":"Culver","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew C.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuel","family":"Della-Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cory A.","family":"Perugino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Admasu","family":"Mamuye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shauna M.","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen","family":"Poma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Greene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"issue":"9976","key":"835_CR1","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/S0140-6736(14)60720-0","volume":"385","author":"T Kamisawa","year":"2015","unstructured":"Kamisawa T, Zen Y, Pillai S, Stone JH. IgG4-related disease. Lancet. 2015;385(9976):1460\u201371.","journal-title":"Lancet"},{"issue":"1","key":"835_CR2","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1016\/S2665-9913(19)30017-7","volume":"1","author":"W Zhang","year":"2019","unstructured":"Zhang W, Stone JH. Management of IgG4-related disease. Lancet Rheumatol. 2019;1(1):e55\u201365.","journal-title":"Lancet Rheumatol"},{"issue":"2","key":"835_CR3","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rkae020","volume":"8","author":"ZS Wallace","year":"2024","unstructured":"Wallace ZS, Katz G, Hernandez-Barco YG, Baker MC. Current and future advances in practice: IgG4-related disease. Rheumatol Adv Pract. 2024;8(2):rkae020.","journal-title":"Rheumatol Adv Pract"},{"issue":"1","key":"835_CR4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/art.41120","volume":"72","author":"ZS Wallace","year":"2020","unstructured":"Wallace ZS, Naden RP, Chari S, Choi H, Della-Torre E, Dicaire JF, et al. The 2019 American College of Rheumatology\/European League Against Rheumatism classification criteria for IgG4-related disease. Arthritis Rheumatol. 2020;72(1):7\u201319.","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"835_CR5","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1002\/art.39205","volume":"67","author":"ZS Wallace","year":"2015","unstructured":"Wallace ZS, Deshpande V, Mattoo H, Mahajan VS, Kulikova M, Pillai S, et al. IgG4-related disease: clinical and laboratory features in one hundred twenty-five patients. Arthritis Rheumatol. 2015;67(9):2466\u201375.","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"835_CR6","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/s41584-020-0500-7","volume":"16","author":"CA Perugino","year":"2020","unstructured":"Perugino CA, Stone JH. IgG4-related disease: an update on pathophysiology and implications for clinical care. Nat Rev Rheumatol. 2020;16(12):702\u201314.","journal-title":"Nat Rev Rheumatol"},{"key":"835_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1067","volume":"369","author":"M Lanzillotta","year":"2020","unstructured":"Lanzillotta M, Mancuso G, Della-Torre E. Advances in the diagnosis and management of IgG4 related disease. BMJ. 2020;369:m1067.","journal-title":"BMJ"},{"issue":"1","key":"835_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s42358-024-00374-y","volume":"64","author":"FAG Pinheiro","year":"2024","unstructured":"Pinheiro FAG, Pereira IA, de Souza AWS, Giardini HAM, Cordeiro RA. IgG4-related disease-rare but you should not forget it. Adv Rheumatol. 2024;64(1):35.","journal-title":"Adv Rheumatol"},{"issue":"7","key":"835_CR9","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1136\/ard-2023-223950","volume":"82","author":"ZS Wallace","year":"2023","unstructured":"Wallace ZS, Miles G, Smolkina E, Petruski-Ivleva N, Madziva D, Cook C, et al. Incidence, prevalence and mortality of IgG4-related disease in the USA: a claims-based analysis of commercially insured adults. Ann Rheum Dis. 2023;82(7):957\u201362.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"835_CR10","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1080\/1744666X.2021.1902310","volume":"17","author":"M Lanzillotta","year":"2021","unstructured":"Lanzillotta M, Fernandez-Codina A, Culver E, Ebbo M, Martinez-Valle F, Schleinitz N, et al. Emerging therapy options for IgG4-related disease. Expert Rev Clin Immunol. 2021;17(5):471\u201383.","journal-title":"Expert Rev Clin Immunol"},{"issue":"11","key":"835_CR11","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/s41577-023-00871-z","volume":"23","author":"T Rispens","year":"2023","unstructured":"Rispens T, Huijbers MG. The unique properties of IgG4 and its roles in health and disease. Nat Rev Immunol. 2023;23(11):763\u201378.","journal-title":"Nat Rev Immunol"},{"key":"835_CR12","volume":"2766","author":"G Mancuso","year":"2024","unstructured":"Mancuso G. A comprehensive review of IgG4 related disease unraveling the role of B and T lymphocytes in the pathogenesis of the disease. J ISSN. 2024;2766:2276.","journal-title":"J ISSN"},{"issue":"3","key":"835_CR13","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.jaci.2014.03.034","volume":"134","author":"H Mattoo","year":"2014","unstructured":"Mattoo H, Mahajan VS, Della-Torre E, Sekigami Y, Carruthers M, Wallace ZS, et al. De novo oligoclonal expansions of circulating plasmablasts in active and relapsing IgG4-related disease. J Allergy Clin Immunol. 2014;134(3):679\u201387.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"835_CR14","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1136\/annrheumdis-2014-205233","volume":"74","author":"ZS Wallace","year":"2015","unstructured":"Wallace ZS, Mattoo H, Carruthers M, Mahajan VS, Della Torre E, Lee H, et al. Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations. Ann Rheum Dis. 2015;74(1):190\u20135.","journal-title":"Ann Rheum Dis"},{"key":"835_CR15","unstructured":"Wallace ZS, Miles G, Smolkina E, Petruski-Ivleva N, Madziva D, Cook C, et al., editors. The epidemiology, clinical outcomes, and healthcare resource utilization of IgG4-related disease among commercially insured people in the United States. Arthritis & Rheumatology; 2022. ACR Convergence 2022."},{"issue":"9","key":"835_CR16","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.cgh.2017.02.007","volume":"15","author":"EL Culver","year":"2017","unstructured":"Culver EL, Sadler R, Bateman AC, Makuch M, Cargill T, Ferry B, et al. Increases in IgE, eosinophils, and mast cells can be used in diagnosis and to predict relapse of IgG4-related disease. Clin Gastroenterol Hepatol. 2017;15(9):1444-1452 e1446.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"835_CR17","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1093\/rheumatology\/keae230","volume":"63","author":"ZS Wallace","year":"2024","unstructured":"Wallace ZS, Miles G, Smolkina E, Petruski-Ivleva N, Madziva D, Guzzo K, et al. The clinical outcomes and healthcare resource utilization in IgG4-related disease: a claims-based analysis of commercially insured adults in the United States. Rheumatology (Oxford). 2024;63(9):2457\u201366.","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"835_CR18","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1002\/art.39132","volume":"67","author":"A Khosroshahi","year":"2015","unstructured":"Khosroshahi A, Wallace ZS, Crowe JL, Akamizu T, Azumi A, Carruthers MN, et al. International consensus guidance statement on the management and treatment of IgG4-related disease. Arthritis Rheumatol. 2015;67(7):1688\u201399.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"835_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/1710-1492-9-30","volume":"9","author":"D Liu","year":"2013","unstructured":"Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013;9(1):30.","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"2","key":"835_CR20","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1093\/mr\/roac141","volume":"33","author":"Y Tanaka","year":"2023","unstructured":"Tanaka Y, Stone JH. Perspectives on current and emerging therapies for immunoglobulin G4-related disease. Mod Rheumatol. 2023;33(2):229\u201336.","journal-title":"Mod Rheumatol"},{"issue":"2","key":"835_CR21","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s40266-024-01172-3","volume":"42","author":"M Akiyama","year":"2025","unstructured":"Akiyama M, Alshehri W, Saito K, Takeuchi T, Kaneko Y. Pharmacological management of IgG4-related disease: from traditional to mechanism-based targeted therapies. Drugs Aging. 2025;42(2):111\u201326.","journal-title":"Drugs Aging"},{"issue":"9","key":"835_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0183844","volume":"12","author":"M Ebbo","year":"2017","unstructured":"Ebbo M, Grados A, Samson M, Groh M, Loundou A, Rigolet A, et al. Long-term efficacy and safety of rituximab in IgG4-related disease: data from a French nationwide study of thirty-three patients. PLoS ONE. 2017;12(9):e0183844.","journal-title":"PLoS ONE"},{"issue":"6","key":"835_CR23","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1136\/annrheumdis-2014-206605","volume":"74","author":"MN Carruthers","year":"2015","unstructured":"Carruthers MN, Topazian MD, Khosroshahi A, Witzig TE, Wallace ZS, Hart PA, et al. Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis. 2015;74(6):1171\u20137.","journal-title":"Ann Rheum Dis"},{"key":"835_CR24","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ejim.2019.12.029","volume":"74","author":"C Campochiaro","year":"2020","unstructured":"Campochiaro C, Della-Torre E, Lanzillotta M, Bozzolo E, Baldissera E, Milani R, et al. Long-term efficacy of maintenance therapy with rituximab for IgG4-related disease. Eur J Intern Med. 2020;74:92\u20138.","journal-title":"Eur J Intern Med"},{"issue":"1","key":"835_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-022-07722-7","volume":"22","author":"F Arnold","year":"2022","unstructured":"Arnold F, Huzly D, Tanriver Y, Welte T. Response to SARS-CoV-2 vaccines in patients receiving B-cell modulating antibodies for renal autoimmune disease. BMC Infect Dis. 2022;22(1):734.","journal-title":"BMC Infect Dis"},{"issue":"10","key":"835_CR26","doi-asserted-by":"publisher","first-page":"6044","DOI":"10.4049\/jimmunol.1004095","volume":"186","author":"D Bedognetti","year":"2011","unstructured":"Bedognetti D, Zoppoli G, Massucco C, Zanardi E, Zupo S, Bruzzone A, et al. Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin\u2019s lymphoma patients treated with rituximab-containing regimens. J Immunol. 2011;186(10):6044\u201355.","journal-title":"J Immunol"},{"issue":"3","key":"835_CR27","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1002\/ana.26309","volume":"91","author":"B Kornek","year":"2022","unstructured":"Kornek B, Leutmezer F, Rommer PS, Koblischke M, Schneider L, Haslacher H, et al. B cell depletion and SARS-CoV-2 vaccine responses in neuroimmunologic patients. Ann Neurol. 2022;91(3):342\u201352.","journal-title":"Ann Neurol"},{"issue":"12","key":"835_CR28","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1056\/NEJMoa2409712","volume":"392","author":"JH Stone","year":"2025","unstructured":"Stone JH, Khosroshahi A, Zhang W, Della Torre E, Okazaki K, Tanaka Y, et al. Inebilizumab for treatment of IgG4-related disease. N Engl J Med. 2025;392(12):1168\u201377.","journal-title":"N Engl J Med"},{"issue":"6","key":"835_CR29","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1007\/s00296-019-04272-1","volume":"39","author":"J Vikse","year":"2019","unstructured":"Vikse J, Jonsdottir K, Kvaloy JT, Wildhagen K, Omdal R. Tolerability and safety of long-term rituximab treatment in systemic inflammatory and autoimmune diseases. Rheumatol Int. 2019;39(6):1083\u201390.","journal-title":"Rheumatol Int"},{"issue":"9","key":"835_CR30","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-021-01037-3","volume":"23","author":"CD Varley","year":"2021","unstructured":"Varley CD, Winthrop KL. Long-term safety of rituximab (risks of viral and opportunistic infections). Curr Rheumatol Rep. 2021;23(9):74.","journal-title":"Curr Rheumatol Rep"},{"issue":"8","key":"835_CR31","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1093\/rheumatology\/kez530","volume":"59","author":"KL Gron","year":"2020","unstructured":"Gron KL, Glintborg B, Norgaard M, Mehnert F, Ostergaard M, Dreyer L, et al. Overall infection risk in rheumatoid arthritis during treatment with abatacept, rituximab and tocilizumab; an observational cohort study. Rheumatology (Oxford). 2020;59(8):1949\u201356.","journal-title":"Rheumatology (Oxford)"},{"issue":"15","key":"835_CR32","doi-asserted-by":"publisher","first-page":"3926","DOI":"10.1016\/j.molimm.2008.06.027","volume":"45","author":"SY Chu","year":"2008","unstructured":"Chu SY, Vostiar I, Karki S, Moore GL, Lazar GA, Pong E, et al. Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcgammaRIIb with Fc-engineered antibodies. Mol Immunol. 2008;45(15):3926\u201333.","journal-title":"Mol Immunol"},{"issue":"9","key":"835_CR33","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1002\/cpdd.1557","volume":"14","author":"X Wang","year":"2025","unstructured":"Wang X, Gao M, Matijevic M, Quinn S, Yamashita M, Arora S, et al. Pharmacokinetics, receptor occupancy, and pharmacodynamics of obexelimab following intravenous administration in adult healthy volunteers and in patients with rheumatoid arthritis. Clin Pharmacol Drug Dev. 2025;14(9):656\u201368.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"7","key":"835_CR34","doi-asserted-by":"publisher","first-page":"4223","DOI":"10.4049\/jimmunol.1003412","volume":"186","author":"HM Horton","year":"2011","unstructured":"Horton HM, Chu SY, Ortiz EC, Pong E, Cemerski S, Leung IW, et al. Antibody-mediated coengagement of FcgammaRIIb and B cell receptor complex suppresses humoral immunity in systemic lupus erythematosus. J Immunol. 2011;186(7):4223\u201333.","journal-title":"J Immunol"},{"issue":"1","key":"835_CR35","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1146\/annurev-immunol-083122-044829","volume":"42","author":"I Abeles","year":"2024","unstructured":"Abeles I, Palma C, Meednu N, Payne AS, Looney RJ, Anolik JH. B cell-directed therapy in autoimmunity. Annu Rev Immunol. 2024;42(1):103\u201326.","journal-title":"Annu Rev Immunol"},{"issue":"8","key":"835_CR36","doi-asserted-by":"publisher","first-page":"e442","DOI":"10.1016\/S2665-9913(23)00157-1","volume":"5","author":"CA Perugino","year":"2023","unstructured":"Perugino CA, Wallace ZS, Zack DJ, Quinn SM, Poma A, Fernandes AD, et al. Evaluation of the safety, efficacy, and mechanism of action of obexelimab for the treatment of patients with IgG4-related disease: an open-label, single-arm, single centre, phase 2 pilot trial. Lancet Rheumatol. 2023;5(8):e442\u201350.","journal-title":"Lancet Rheumatol"},{"issue":"2","key":"835_CR37","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s12325-024-03067-6","volume":"42","author":"X Wang","year":"2025","unstructured":"Wang X, Kirk R, Matijevic M, Gao M, Poma A, Quinn S, et al. Pharmacokinetics, pharmacodynamics, bioavailability, and immunogenicity of obexelimab following subcutaneous administration in healthy Japanese and non-Japanese volunteers. Adv Ther. 2025;42(2):813\u201329.","journal-title":"Adv Ther"},{"key":"835_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2020.100075","volume":"4","author":"SY Chu","year":"2021","unstructured":"Chu SY, Pong E, Bonzon C, Yu N, Jacob CO, Chalmers SA, et al. Inhibition of B cell activation following in vivo co-engagement of B cell antigen receptor and Fcgamma receptor IIb in non-autoimmune-prone and SLE-prone mice. J Transl Autoimmun. 2021;4:100075.","journal-title":"J Transl Autoimmun"},{"issue":"4","key":"835_CR39","doi-asserted-by":"publisher","first-page":"991","DOI":"10.4161\/mabs.28841","volume":"6","author":"D Szili","year":"2014","unstructured":"Szili D, Cserhalmi M, Banko Z, Nagy G, Szymkowski DE, Sarmay G. Suppression of innate and adaptive B cell activation pathways by antibody coengagement of FcgammaRIIb and CD19. MAbs. 2014;6(4):991\u20139.","journal-title":"MAbs"},{"issue":"12","key":"835_CR40","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1002\/art.42652","volume":"75","author":"JT Merrill","year":"2023","unstructured":"Merrill JT, Guthridge J, Smith M, June J, Koumpouras F, Machua W, et al. Obexelimab in systemic lupus erythematosus with exploration of response based on gene pathway co-expression patterns: a double-blind, randomized, placebo-controlled, phase 2 trial. Arthritis Rheum. 2023;75(12):2185\u201394.","journal-title":"Arthritis Rheum"},{"key":"835_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.152010","volume":"55","author":"JH Stone","year":"2022","unstructured":"Stone JH, McDowell PJ, Jayne DRW, Merkel PA, Robson J, Patel NJ, et al. The glucocorticoid toxicity index: measuring change in glucocorticoid toxicity over time. Semin Arthritis Rheum. 2022;55:152010.","journal-title":"Semin Arthritis Rheum"},{"key":"835_CR42","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/259408","volume":"2012","author":"MN Carruthers","year":"2012","unstructured":"Carruthers MN, Stone JH, Deshpande V, Khosroshahi A. Development of an IgG4-RD Responder Index. Int J Rheumatol. 2012;2012:259408.","journal-title":"Int J Rheumatol"},{"issue":"11","key":"835_CR43","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1002\/acr.23543","volume":"70","author":"ZS Wallace","year":"2018","unstructured":"Wallace ZS, Khosroshahi A, Carruthers MD, Perugino CA, Choi H, Campochiaro C, et al. An international multispecialty validation study of the IgG4-related disease Responder Index. Arthritis Care Res (Hoboken). 2018;70(11):1671\u20138.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"835_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2023.152253","volume":"63","author":"ZS Wallace","year":"2023","unstructured":"Wallace ZS, McMahon GA, Hang B, Fu X, Harkness T, Donelan K, et al. Assessment of patient-reported symptoms and distress in IgG4-related disease (IgG4-RD): development, clinical validation, and content validation of the IgG4-RD Symptom Severity Index. Semin Arthritis Rheum. 2023;63:152253.","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"835_CR45","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s40259-018-0295-0","volume":"32","author":"B Bittner","year":"2018","unstructured":"Bittner B, Richter W, Schmidt J. Subcutaneous administration of biotherapeutics: an overview of current challenges and opportunities. BioDrugs. 2018;32(5):425\u201340.","journal-title":"BioDrugs"},{"key":"835_CR46","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/B978-0-12-823741-0.00002-6","volume-title":"Formulation and device lifecycle management of biotherapeutics","author":"B Bittner","year":"2022","unstructured":"Bittner B, Schmidt J. Clinical development of subcutaneous dosing alternatives to established intravenous formulations for monoclonal antibodies\u2014pharmacokinetic-based bridging approach. In: Bittner B, Schmidt J, editors. Formulation and device lifecycle management of biotherapeutics. New York: Academic Press; 2022. p. 47\u201383."},{"key":"835_CR47","first-page":"579","volume-title":"Challenges in protein product development. AAPS advances in the pharmaceutical sciences series","author":"C Mueller","year":"2018","unstructured":"Mueller C, Adler M. Switching from an IV to an SC formulation\u2014considerations for formulation development and formulation bridging. In: Warne NW, Mahler H-C, editors. Challenges in protein product development. AAPS advances in the pharmaceutical sciences series. Cham: Springer; 2018. p. 579\u201390."},{"issue":"5","key":"835_CR48","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1016\/j.ekir.2025.02.002","volume":"10","author":"O Efe","year":"2025","unstructured":"Efe O, Sauvage G, Jeyabalan A, Al Jurdi A, Seethapathy HS, Cosgrove K, et al. Persistent B cell depletion after rituximab for autoimmune and glomerular diseases: a case series. Kidney Int Rep. 2025;10(5):1441\u20139.","journal-title":"Kidney Int Rep"},{"issue":"1","key":"835_CR49","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200056","volume":"10","author":"C Starvaggi Cucuzza","year":"2023","unstructured":"Starvaggi Cucuzza C, Longinetti E, Ruffin N, Evertsson B, Kockum I, Jagodic M, et al. Sustained low relapse rate with highly variable B-cell repopulation dynamics with extended rituximab dosing intervals in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2023;10(1):e200056.","journal-title":"Neurol Neuroimmunol Neuroinflamm"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-026-00835-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-026-00835-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-026-00835-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T10:02:29Z","timestamp":1779530549000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-026-00835-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,16]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["835"],"URL":"https:\/\/doi.org\/10.1007\/s40744-026-00835-4","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,16]]},"assertion":[{"value":"22 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Emma L. Culver has participated in advisory boards and consulting for Amgen, Zenas BioPharma, Sanofi, Acepodia, Ipsen, Mirum, GSK, Dr Falk Pharma, and Gilead, and receives research support from the NIHR Oxford Biomedical Research Centre. Matthew C. Baker has received fees from Amgen, Sanofi, Zenas BioPharma, argenx, Eli Lilly, Gilead, and Neurocrine. Emanuel Della-Torre has participated in advisory boards and consulting for Amgen, Zenas BioPharma, Sanofi, and Acepodia. Wen Zhang has participated in advisory boards and consulting for Amgen, Zenas BioPharma, Sanofi, and Acepodia. Cory A. Perugino has received consulting fees from Amgen, Sanofi, and Acepodia. Audrey Wells, Admasu Mamuye, Shauna M. Quinn, Allen Poma, and Thomas J. Greene are employees of Zenas BioPharma, Inc. and may hold stock or stock options in the company. John H. Stone has received grants from the National Institutes of Health (UM1 AI144295) and Q32Bio, serves as Chair of a Data and Safety Monitoring Board for Merck, and has received consulting fees from Amgen, Zenas, Sanofi, AcepodiaBio, Novartis, HingeBio, ZipBio, and Argenx.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The INDIGO study protocol has been approved by relevant health authorities and institutional review boards and was activated at 114 sites in Argentina, Canada, China, France, Germany, Hong Kong, Hungary, Italy, Japan, Mexico, Netherlands, Poland, South Korea, Spain, Sweden, Taiwan, Turkey, United Kingdom, and United States. The trial is conducted in accordance with consensus ethical principles derived from the Declaration of Helsinki and applicable International Council for Harmonisation\u2013Good Clinical Practice (ICH GCP) guidelines. All patients provide written informed consent prior to any study procedures.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}